المؤلفون: Zobair M. Younossi, Saleh A. AlQahtani, Jesús Funuyet-Salas, Manuel Romero-Gómez, Yusuf Yilmaz, Caglayan Keklikkiran, Khalid Alswat, Ming-Lung Yu, Chun-Jen Liu, Jian-Gao Fan, Ming-Hua Zheng, Patrizia Burra, Sven M. Francque, Laurent Castera, Jörn M. Schattenberg, Philip N. Newsome, Alina M. Allen, Mohamed El-Kassas, Sombat Treeprasertsuk, Saeed Hameed, Vincent Wai-Sun Wong, Shira Zelber-Sagi, Hirokazu Takahashi, Takumi Kawaguchi, Marlen I. Castellanos Fernández, Ajay Duseja, Marco Arrese, Mary Rinella, Ashwani K. Singal, Stuart C. Gordon, Michael Fuchs, Wayne Eskridge, Naim Alkhouri, Kenneth Cusi, Rohit Loomba, Jane Ranagan, Achim Kautz, Janus P. Ong, Marcelo Kugelmas, Yuichiro Eguchi, Moises Diago, Lynn Gerber, Brian Lam, Lisa Fornaresio, Fatema Nader, C. Wendy Spearman, Stuart K. Roberts, Wah-Kheong Chan, Marcelo Silva, Andrei Racila, Pegah Golabi, Prooksa Ananchuensook, Linda Henry, Maria Stepanova, Patrizia Carrieri, Jeffrey V. Lazarus

المصدر: JHEP Reports, Vol 6, Iss 7, Pp 101066- (2024)

مصطلحات موضوعية: patient-reported outcomes, metabolic liver disease, NASH, MASLD, MASH, SLD, Diseases of the digestive system. Gastroenterology, RC799-869

الوصف: Background & Aims: Patients with nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic liver disease (MASLD) face a multifaceted disease burden which includes impaired health-related quality of life (HRQL) and potential stigmatization. We aimed to assess the burden of liver disease in patients with NAFLD and the relationship between experience of stigma and HRQL. Methods: Members of the Global NASH Council created a survey about disease burden in NAFLD. Participants completed a 35-item questionnaire to assess liver disease burden (LDB) (seven domains), the 36-item CLDQ-NASH (six domains) survey to assess HRQL and reported their experience with stigmatization and discrimination. Results: A total of 2,117 patients with NAFLD from 24 countries completed the LDB survey (48% Middle East and North Africa, 18% Europe, 16% USA, 18% Asia) and 778 competed CLDQ-NASH. Of the study group, 9% reported stigma due to NAFLD and 26% due to obesity. Participants who reported stigmatization due to NAFLD had substantially lower CLDQ-NASH scores (all p

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2589555924000673Test; https://doaj.org/toc/2589-5559Test

الوصول الحر: https://doaj.org/article/89eb6d0343c440378b078cf55412cc72Test

المؤلفون: Michael H. Le, Linda Henry, Mindie H. Nguyen

المصدر: Clinical and Molecular Hepatology, Vol 30, Iss 2, Pp 284-286 (2024)

مصطلحات موضوعية: nafld, epidemiology, Diseases of the digestive system. Gastroenterology, RC799-869

وصف الملف: electronic resource

العلاقة: http://e-cmh.org/upload/pdf/cmh-2024-0108.pdfTest; https://doaj.org/toc/2287-2728Test; https://doaj.org/toc/2287-285XTest

الوصول الحر: https://doaj.org/article/71a28095dfb543c68cb057837b3a7cf8Test

المؤلفون: Zobair M. Younossi, Maria Stepanova, Brian Lam, Rebecca Cable, Sean Felix, Thomas Jeffers, Elena Younossi, Huong Pham, Manirath Srishord, Patrick Austin, Michael Estep, Kathy Terra, Carey Escheik, Leyla deAvila, Pegah Golabi, Andrej Kolacevski, Andrei Racila, Linda Henry, Lynn Gerber

المصدر: Hepatology Communications, Vol 6, Iss 11, Pp 3062-3072 (2022)

مصطلحات موضوعية: Diseases of the digestive system. Gastroenterology, RC799-869

الوصف: The impact of the coronavirus disease 2019 (COVID‐19) pandemic among patients with chronic liver disease is unknown. Given the high prevalence of nonalcoholic fatty liver disease (NAFLD), we determined the predictors of mortality and hospital resource use among patients with NAFLD admitted with COVID‐19 by using electronic medical records data for adult patients with COVID‐19 hospitalized in a multihospital health system who were discharged between March and December 2020. NAFLD was diagnosed by imaging or liver biopsy without other liver diseases. Charlson’s comorbidity index (CCI) and Elixhauser comorbidity index (ECI) scores were calculated. In the study sample, among the 4,835 patients hospitalized for COVID‐19, 553 had NAFLD (age: 55 ± 16 years, 51% male, 17% White, 11% Black, 58% Hispanic, 8% Asian, 5% from congregated living, 58% obese, 15% morbid obesity [body mass index ≥ 40], 51% type 2 diabetes, 63% hypertension, mean [SD] baseline CCI of 3.9 [3.2], and baseline ECI of 13.4 [11.3]). On admission, patients with NAFLD had more respiratory symptoms, higher body temperature and heart rate, higher alanine aminotransferase and aspartate aminotransferase than non‐NAFLD controls (n = 2,736; P 0.05). Conclusion: Patients with NAFLD infected with COVID‐19 tend to be sicker on admission and require more hospital resource use. Independent predictors of mortality included higher FIB‐4 and multimorbidity scores, morbid obesity, older age, and hypoxemia on admission.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2471-254XTest

الوصول الحر: https://doaj.org/article/6dc06c8e1ef64e35b359559ab68fca45Test

المؤلفون: James M. Paik, Katherine E Eberly, Khaled Kabbara, Michael Harring, Youssef Younossi, Linda Henry, Manisha Verma, Zobair M. Younossi

المصدر: Annals of Hepatology, Vol 28, Iss 4, Pp 101108- (2023)

مصطلحات موضوعية: Mortality, Cirrhosis complications, NAFLD, Specialties of internal medicine, RC581-951

الوصف: Introduction and Objectives: Data about 30-day readmission for patients with chronic liver disease (CLD) and their contribution to CLD healthcare burden are sparse. Patterns, diagnoses, timing and predictors of 30-day readmissions for CLD from 2010-2017 were assessed. Materials and Methods: Nationwide Readmission Database (NRD) is an all-payer, all-ages, longitudinal administrative database, representing 35 million discharges in the US population yearly. We identified unique patients discharged with CLD including hepatitis B (HBV) and C (HCV), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) from 2010 through 2017. Survey-weight adjusted multivariable analyses were used. Results: From 2010 to 2017, the 30-day readmission rate for CLD decreased from 18.4% to 17.8% (p=.008), while increasing for NAFLD from 17.0% to 19. 9% (p

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S1665268123002120Test; https://doaj.org/toc/1665-2681Test

الوصول الحر: https://doaj.org/article/a73fe3dccbab44c9bef4b104a8f7a692Test

المؤلفون: Haesuk Park, Wei-Hsuan Lo-Ciganic, James Huang, Yonghui Wu, Linda Henry, Joy Peter, Mark Sulkowski, David R. Nelson

المصدر: Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract Despite the availability of efficacious direct-acting antiviral (DAA) therapy, the number of people infected with hepatitis C virus (HCV) continues to rise, and HCV remains a leading cause of liver-related morbidity, liver transplantation, and mortality. We developed and validated machine learning (ML) algorithms to predict DAA treatment failure. Using the HCV-TARGET registry of adults who initiated all-oral DAA treatment, we developed elastic net (EN), random forest (RF), gradient boosting machine (GBM), and feedforward neural network (FNN) ML algorithms. Model performances were compared with multivariable logistic regression (MLR) by assessing C statistics and other prediction evaluation metrics. Among 6525 HCV-infected adults, 308 patients (4.7%) experienced DAA treatment failure. ML models performed similarly in predicting DAA treatment failure (C statistic [95% CI]: EN, 0.74 [0.69–0.79]; RF, 0.74 [0.69–0.80]; GBM, 0.72 [0.67–0.78]; FNN, 0.75 [0.70–0.80]), and all 4 outperformed MLR (C statistic [95% CI]: 0.51 [0.46–0.57]), and EN used the fewest predictors (n = 27). With Youden index, the EN had 58.4% sensitivity and 77.8% specificity, and nine patients were needed to evaluate to identify 1 DAA treatment failure. Over 60% treatment failure were classified in top three risk decile subgroups. EN-identified predictors included male sex, treatment 1.2 g/dL, advanced liver disease, and use of tobacco, alcohol, or vitamins. Addressing modifiable factors of DAA treatment failure may reduce the burden of retreatment. Machine learning algorithms have the potential to inform public health policies regarding curative treatment of HCV.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/4c4faf64ed874da28ce08ccc02fc2f02Test

المؤلفون: Maria Stepanova, Brian Lam, Elena Younossi, Sean Felix, Mariam Ziayee, Jillian Price, Huong Pham, Leyla de Avila, Kathy Terra, Patrick Austin, Thomas Jeffers, Carey Escheik, Pegah Golabi, Rebecca Cable, Manirath Srishord, Chapy Venkatesan, Linda Henry, Lynn Gerber, Zobair M. Younossi

المصدر: BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-11 (2022)

مصطلحات موضوعية: Emerging diseases, Healthcare utilization, Multimorbidity, Pneumonia, Immunization, Public health, Infectious and parasitic diseases, RC109-216

الوصف: Abstract Background COVID-19 outcomes among hospitalized patients may have changed due to new variants, therapies and vaccine availability. We assessed outcomes of adults hospitalized with COVID-19 from March 2020–February 2022. Methods Data were retrieved from electronic health medical records of adult COVID-19 patients hospitalized in a large community health system. Duration was split into March 2020–June 2021 (pre-Delta period), July–November 2021 (Delta period), and December 2021–February 2022 (Omicron period). Results Of included patients (n = 9582), 75% were admitted during pre-Delta, 9% during Delta, 16% during Omicron period. The COVID-positive inpatients were oldest during Omicron period but had lowest rates of COVID pneumonia and resource utilization (p

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2334Test

الوصول الحر: https://doaj.org/article/c669c9b3af3e4a2286a0e2e024489b41Test

المؤلفون: Zobair Younossi, Linda Henry

المصدر: European Medical Journal Hepatology, Pp 74-83 (2022)

مصطلحات موضوعية: Diseases of the digestive system. Gastroenterology, RC799-869

الوصف: Non-alcoholic steatohepatitis (NASH) is the potentially progressive form of non-alcoholic fatty liver disease (NAFLD). NAFLD and NASH are very common in most regions of the world and are on trajectory to become the most common liver disease at a global scale. Risk for high prevalence and progressiveness include visceral obesity and Type 2 diabetes. The conundrum of NAFLD is related to the rapid increase in its global burden with very low awareness among most general providers, as well as a lack of widespread availability of fully validated non-invasive diagnostic and prognostic tests and limited treatment options. Currently, lifestyle modification with diet and exercise are the best options. A large number of clinical trials are being developed to provide drug therapeutic options with patients with NASH and moderate to advanced fibrosis.

وصف الملف: electronic resource

العلاقة: https://www.emjreviews.com/hepatology/article/non-alcoholic-steatohepatitis-global-impact-and-clinical-consequences-j070122Test/; https://doaj.org/toc/2053-4221Test

الوصول الحر: https://doaj.org/article/9d2e68f1dd964414a6742bdddf8c7b6bTest

المؤلفون: Aditya Kasarabada, Kimberly Barker, Theresa Ganoe, Lindsay Clevenger, Cristina Visco, Jessica Gibson, Rahim Karimi, Negar Naderi, Brian Lam, Maria Stepanova, Linda Henry, Christopher King, Mehul Desai

المصدر: PLoS ONE, Vol 18, Iss 2 (2023)

مصطلحات موضوعية: Medicine, Science

الوصف: Background/Aim We investigated the association of noninvasive oxygenation support [high flow nasal cannula (HFNC) and BiPAP], timing of invasive mechanical ventilation (IMV), and inpatient mortality among patients hospitalized with COVID-19. Methods Retrospective chart review study of patients hospitalized with COVID-19 (ICD-10 code U07.1) and received IMV from March 2020-October 2021. Charlson comorbidity index (CCI) was calculated; Obesity defined as body mass index (BMI) ≥ 30 kg/m2; morbid obesity was BMI ≥ 40 kg/m2. Clinical parameters/vital signs recorded at time of admission. Results 709 COVID-19 patients underwent IMV, predominantly admitted from March-May 2020 (45%), average age 62±15 years, 67% male, 37% Hispanic, and 9% from group living settings. 44% had obesity, 11% had morbid obesity, 55% had type II diabetes, 75% had hypertension, and average CCI was 3.65 (SD = 3.11). Crude mortality rate was 56%. Close linear association of age with inpatient-mortality risk was found [OR (95% CI) = 1.35 (1.27–1.44) per 5 years, pConclusion Time spent on noninvasive oxygenation support [as defined by high flow nasal cannula (HFNC) and BiPAP] prior to IMV increased mortality risk. Research for the generalizability of our findings to other respiratory failure patient populations is needed.

وصف الملف: electronic resource

العلاقة: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934441/?tool=EBITest; https://doaj.org/toc/1932-6203Test

الوصول الحر: https://doaj.org/article/340e53cbe7774b81b02090216dc104cbTest

المؤلفون: Saleh A. Alqahtani, James M. Paik, Rakesh Biswas, Tamoore Arshad, Linda Henry, Zobair M. Younossi

المصدر: Hepatology Communications, Vol 5, Iss 11, Pp 1833-1847 (2021)

مصطلحات موضوعية: Diseases of the digestive system. Gastroenterology, RC799-869

الوصف: Population‐based studies that estimate awareness of nonalcoholic fatty liver disease (NAFLD) in the United States are scant. We aimed to understand public awareness of NAFLD and its temporal trends. Our study included 11,700 adults (18+ years old) from five National Health and Nutrition Examination Surveys (2007‐2016). NAFLD was determined by the improved Fatty Liver Index for the multiethnic U.S. population (US‐FLI) in the absence of secondary causes of liver disease. Overall prevalence of NAFLD, hepatitis C virus, and hepatitis B virus were 36.6%, 1.02% and 0.35%, respectively. From 2007‐2008 to 2015‐2016, awareness of liver disease among adults with NAFLD improved from 4.4% to 6.3% (trend P = 0.026) but 4 to 10 times lower than awareness about viral hepatitis. In 2015‐2016, among adults with NAFLD, awareness of liver disease was lower among young adults (aged 18‐29 years) compared with those aged ≥ 30 years (0% vs. 6.9%) and lower among non‐Hispanic Blacks compared with other races (0.7% vs. 6.6%) (all P

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2471-254XTest

الوصول الحر: https://doaj.org/article/9348830dce95453ea7c09a902438a255Test

المؤلفون: Tamoore Arshad, James M. Paik, Rakesh Biswas, Saleh A. Alqahtani, Linda Henry, Zobair M. Younossi

المصدر: Hepatology Communications, Vol 5, Iss 10, Pp 1676-1688 (2021)

مصطلحات موضوعية: Diseases of the digestive system. Gastroenterology, RC799-869

الوصف: Understanding the burden of NAFLD among adolescents and young adults has become increasingly relevant. Our aim was to estimate the prevalence of NAFLD among adolescents and young adults in the United States. Data were obtained from National Health and Nutrition Examination Survey from 2007‐2016. Adolescents and young adults aged 12 to 29 years were included. NAFLD was determined by the U.S. Fatty Liver Index in the absence of secondary causes of liver disease, and the differences in prevalence trends were analyzed based on age, gender, and race. Complete data were available for 4,654 adolescents and young adults (mean age 21 years; 50.9% male; 56.8% White, 20.9% Hispanic, and 13.3% Black). The overall prevalence of NAFLD among adolescents and young adults was 18.5%, ranging from 13.2% among early and middle adolescents (12‐17 years) to 18.7% among late adolescents and young adults (18‐24 years), to 24.0% among older young adults (25‐30 years) (trend P 0.80). In contrast, NAFLD prevalence among late adolescents increased (trend P = 0.018). In fact, White and Hispanic late adolescents were the drivers behind this increase in the prevalence of NAFLD. Conclusion: These data indicate an increasing trend in NAFLD prevalence among 18‐24‐year‐olds. These data have important public health and policy implications.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2471-254XTest

الوصول الحر: https://doaj.org/article/53f67848c5f249ba93ca277ee1817a20Test